经导管主动脉瓣植入术后最佳抗栓治疗:事实与不确定性
综述探讨TAVI患者血栓栓塞与出血事件负担,基于注册研究和近期随机对照试验总结当前最佳抗栓策略,指出该人群年龄常超80岁且兼具高出血与高血栓风险,并讨论实践指导与知识空白。
要点
- TAVI患者多超80岁,高出血与高血栓风险并存,抗栓需平衡。
- 血栓栓塞事件(卒中、瓣膜血栓)仍常见,抗栓预防常规使用。
- 抗栓药物增加出血,尤其合并获得性vWF缺陷和血管发育不良者。
核心结论
- TAVI术后血栓栓塞事件仍常见,抗栓治疗需在血栓预防与出血风险间平衡。
- 当前最佳抗栓策略基于注册研究和近期随机对照试验,但存在知识空白。
研究设计与样本
- 综述类文章,讨论TAVI患者血栓栓塞与出血事件影响、当前抗栓治疗证据及实践指导。
- 证据来源包括注册研究和近期随机对照试验。
主要发现
- TAVI患者多数超过80岁,同时具有高出血和高血栓风险。
- 尽管手术安全性提高,卒中及(亚临床)瓣膜血栓等血栓栓塞事件仍普遍。
- 抗栓药物增加出血,尤其在该人群独特的主动脉瓣狭窄相关出血特征(如获得性血管性血友病因子缺陷和血管发育不良)背景下。
临床怎么用
- 基于注册研究和近期随机对照试验证据,为TAVI高危患者提供实用抗栓治疗指导。
局限性
- 抗栓治疗领域存在知识空白,需未来研究填补。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure, which is used frequently in patients with symptomatic severe aortic valve stenosis. Most patients undergoing TAVI are over 80 years of age with a high bleeding as well as thrombotic risk. Despite the increasing safety of the procedure, thromboembolic events [stroke, (subclinical) valve thrombosis] remain prevalent. As a consequence, antithrombotic prophylaxis is routinely used and only recently new data on the efficacy and safety of antithrombotic drugs has become available. On the other hand, these antithrombotic drugs increase bleeding in a population with unique aortic stenosis-related bleeding characteristics (such as acquired von Willebrand factor defect and angiodysplasia). In this review, we discuss the impact of thromboembolic and bleeding events, the current optimal antithrombotic therapy based on registries and recent randomized controlled trials, as well as try to give a practical guide how to treat these high-risk patients. Finally, we discuss knowledge gaps and future research needed to fill these gaps.
引用
- Ten Berg J, Rocca B, Angiolillo DJ, et al. The search for optimal antithrombotic therapy in transcatheter aortic valve implantation: facts and uncertainties. Eur Heart J. 2022. PMID: 36130256. doi:10.1093/eurheartj/ehac385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。